Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for dronabinol

  1. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

    NICE guideline
    Last updated
    22 March 2021
    View recommendations

    Sections for NG144

  2. For adults with fibromyalgia or persistent treatment-resistant neuropathic pain, what is the clinical and cost effectiveness of cannabidiol (CBD), containing no, or traces of, delta-9-tetrahydrocannabinol (THC), as an add-on to standard treatment?

    resources. The evidence included CBD in combination with THC, THC alone, dronabinol and nabilone so the committee named these products...

    Research recommendation
    Published
    10 February 2020

  3. For children and young people with intractable cancer-related pain and pain associated with specific diseases (such as epidermolysis bullosa), what is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on to standard treatment to improve symptoms compared with treatment with standard care?

    resources. The evidence included CBD in combination with THC, THC alone, dronabinol and nabilone so the committee named these products...

    Research recommendation
    Published
    10 February 2020